AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7897712 — intervention group
Group type: EXPERIMENTAL
Intervention: Site change every 48 hours of the CVC
Number of subjects: 42
Study 7897712 — intervention group
Group type: COMPARATOR
Intervention: Wire guide exchange of the CVC every 48 hours at the same site
Number of subjects: 42
Study 2523321 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly (increased to 2.5 mg three times a week if amenorrhea not achieved)
Number of subjects: 39
Study 2523321 — intervention group
Group type: COMPARATOR
Intervention: Danazol 600 mg/day (increased to 800 mg/day if amenorrhea not achieved)
Number of subjects: 39
Study 869121 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft dressing
Number of subjects: 51
Study 869121 — intervention group
Group type: COMPARATOR
Intervention: Plaster dressing
Number of subjects: 51
Study 31892920 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 60
Study 31892920 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Change (GSC)
Number of subjects: 60
Study 31892920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GSC and NRT
Number of subjects: 60
Study 28727541 — intervention group
Group type: EXPERIMENTAL
Intervention: High Health Burden subgroup
Number of subjects: 397
Study 28727541 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Smokers subgroup
Number of subjects: 397
Study 28727541 — intervention group
Group type: COMPARATOR
Intervention: Heavy Smoking Drinking Depressed subgroup
Number of subjects: 397
Study 26256429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER 40 mg daily
Number of subjects: 0
Study 26256429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER 80 mg daily
Number of subjects: 0
Study 26256429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER 120 mg daily
Number of subjects: 0
Study 26256429 — intervention group
Group type: COMPARATOR
Intervention: Levomilnacipran ER (25-100 mg single dose)
Number of subjects: 0
Study 26256429 — intervention group
Group type: COMPARATOR
Intervention: Levomilnacipran ER (25-300 mg multiple doses)
Number of subjects: 0
Study 26256429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER (40, 80, 120 mg daily for 8 weeks)
Number of subjects: 0
Study 26256429 — intervention group
Group type: COMPARATOR
Intervention: In vitro NE and 5-HT transporter inhibition
Number of subjects: 0
Study 23439629 — intervention group
Group type: EXPERIMENTAL
Intervention: De qi acupuncture (needles manipulated until de qi was reached)
Number of subjects: 338
Study 23439629 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (needles inserted without manipulation)
Number of subjects: 338
Study 19998046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sucralfate lotion
Number of subjects: 21
Study 19998046 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrophotometric evaluation
Number of subjects: 21
Study 19998046 — intervention group
Group type: COMPARATOR
Intervention: RTOG acute toxicity scale
Number of subjects: 21
Study 19379610 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based staging
Number of subjects: 89
Study 17378519 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care program (10-month duration)
Number of subjects: 97
Study 17378519 — intervention group
Group type: COMPARATOR
Intervention: Standard checkups
Number of subjects: 97
Study 15722782 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (e.g., anticonvulsants, lidocaine patch 5%, antidepressants, opioids, tramadol)
Number of subjects: 0
Study 15722782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatments (e.g., peripheral or neuraxial nerve blockade, implanted spinal cord stimulators, implanted intrathecal catheters)
Number of subjects: 0
Study 12482209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for migraine prophylaxis
Number of subjects: 119
Study 12482209 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 119
Study 12482209 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (before treatment)
Number of subjects: 119
Study 12482209 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (before treatment)
Number of subjects: 119
Study 9463745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural fluid pseudouridine concentrations in malignant group
Number of subjects: 77
Study 9463745 — intervention group
Group type: COMPARATOR
Intervention: Pleural fluid pseudouridine concentrations in non-malignant group
Number of subjects: 77
Study 9463745 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 77
Study 9463745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural fluid pseudouridine concentration > 65 mumol/L
Number of subjects: 77
Study 7664723 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/d of acetylsalicylic acid
Number of subjects: 10
Study 2764127 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl, 600 mg
Number of subjects: 94
Study 2764127 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 94
Study 2764127 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (group 1)
Number of subjects: 94
Study 2764127 — intervention group
Group type: COMPARATOR
Intervention: Intermittent claudications (group 2)
Number of subjects: 94
Study 2764127 — intervention group
Group type: COMPARATOR
Intervention: Rest pain (group 3)
Number of subjects: 94
Study 2764127 — intervention group
Group type: COMPARATOR
Intervention: Severe ischemic skin changes (group 4)
Number of subjects: 94
Study 1097036 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 0
Study 1097036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar cane residue (bagasse)
Number of subjects: 0
Study 1097036 — intervention group
Group type: COMPARATOR
Intervention: Control (normal diet without fibre supplements)
Number of subjects: 0
Study 31492552 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherwort injection (MI)
Number of subjects: 408
Study 31492552 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 408
Study 30972997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative aerobic exercise (3 months treadmill training)
Number of subjects: 90
Study 29060810 — intervention group
Group type: EXPERIMENTAL
Intervention: NFB group (real-time fMRI neurofeedback)
Number of subjects: 41
Study 29060810 — intervention group
Group type: COMPARATOR
Intervention: CTRL group (sham feedback)
Number of subjects: 41
Study 25620016 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous coupler therapy
Number of subjects: 195
Study 25620016 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 195
Study 23572165 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 55
Study 23572165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21799455 — intervention group
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System (intraoral bone conduction device)
Number of subjects: 22
Study 19663196 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprasol 20 mg twice a day + BTD 240 mg twice a day
Number of subjects: 50
Study 19663196 — intervention group
Group type: COMPARATOR
Intervention: omeprasol 20 mg twice a day
Number of subjects: 50
Study 14976272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 171
Study 14976272 — intervention group
Group type: COMPARATOR
Intervention: Guided Support Groups (SG)
Number of subjects: 171
Study 14976272 — intervention group
Group type: COMPARATOR
Intervention: Natural Course (NC)
Number of subjects: 171
Study 10024613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 220
Study 10024613 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (7.8 mg daily)
Number of subjects: 220
Study 10024613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 10024613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 220
Study 10024613 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 220
Study 10024613 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants (overall)
Number of subjects: 220
Study 7675298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injections of methylcobalamin (MB12)
Number of subjects: 5
Study 7675298 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline injections (placebo trial)
Number of subjects: 5
Study 2254759 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of recombinant human granulocyte-macrophage colony-stimulating factor
Number of subjects: 61
Study 2254759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor
Number of subjects: 61
Study 7307238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-motor education programme provided by an occupational therapist during prenatal classes.
Number of subjects: 0
Study 7307238 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 30766533 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β blocker anakinra
Number of subjects: 0
Study 30766533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28188670 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV/CPA (100 mg/day for 7 days before vaccination)
Number of subjects: 49
Study 28188670 — intervention group
Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 49
Study 25995280 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Activity, and Breastfeeding intervention (FAB) and Combination intervention (Combo)
Number of subjects: 802
Study 25995280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) and Infant Sleep education intervention (Sleep)
Number of subjects: 802
Study 25995280 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB and Combo groups combined
Number of subjects: 802
Study 25995280 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 802
Study 24975855 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous angioplasty
Number of subjects: 29
Study 24975855 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 29
Study 21116121 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of absorbing materials for skin decontamination
Number of subjects: 0
Study 21116121 — intervention group
Group type: COMPARATOR
Intervention: Traditional washing procedure
Number of subjects: 0
Study 20532103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg, maximum dose 12 mg)
Number of subjects: 62
Study 20532103 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 62
Study 17519312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg daily)
Number of subjects: 30
Study 17519312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17519312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 15303787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur (used alone or in combination with sodium sulfacetamide or salicylic acid)
Number of subjects: 0
Study 15303787 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied sulfur
Number of subjects: 0
Study 11435049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand technique (LW group)
Number of subjects: 60
Study 11435049 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscope (LS group)
Number of subjects: 60
Study 10052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg x kg(‐1))
Number of subjects: 6
Study 10052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg x kg(‐1))
Number of subjects: 6
Study 10052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus Atropine
Number of subjects: 6
Study 10052663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Propranolol plus Atropine
Number of subjects: 6
Study 10052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial and double blockade during exercise
Number of subjects: 6
Study 7982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words interpreted as proper names
Number of subjects: 0
Study 7982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words interpreted as adjectives/mass nouns
Number of subjects: 0
Study 7982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words for non-pet animals not described as possessed
Number of subjects: 0
Study 7982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words for simple or complex artifacts
Number of subjects: 0
Study 29307087 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 376
Study 29307087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 27046670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 63
Study 27046670 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 63
Study 26580866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional ablative Er:YAG 2940-nm laser (FELR) with topical anti-aging and anti-pigment agents followed by ultrasound treatment
Number of subjects: 15
Study 26580866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment following FELR and topical agents
Number of subjects: 15
Study 26580866 — intervention group
Group type: COMPARATOR
Intervention: FELR and topical agents alone
Number of subjects: 15
Study 23700011 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐cis β‐carotene (300 mg daily for 90 days)
Number of subjects: 34
Study 23700011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, daily for 90 days)
Number of subjects: 34
Study 23700011 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐cis β‐carotene
Number of subjects: 34
Study 23700011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 98
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 98
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 98
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug therapy
Number of subjects: 98
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VPA-LEV
Number of subjects: 98
Study 20502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) for the first 2 months
Number of subjects: 98
Study 20502135 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 98
Study 19509119 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 4407
Study 19509119 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 4407
Study 17184146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment for three months
Number of subjects: 10
Study 17184146 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 10
Study 15058374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine mouth rinse (test group)
Number of subjects: 33
Study 15058374 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (control group)
Number of subjects: 33
Study 11317112 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physiotherapy
Number of subjects: 148
Study 11317112 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle reconditioning on devices
Number of subjects: 148
Study 11317112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact aerobics
Number of subjects: 148
Study 9135178 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with bupivacaine 0.5% followed by bupivacaine 0.375% infusion
Number of subjects: 16
Study 9135178 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 16
Study 9135178 — intervention group
Group type: COMPARATOR
Intervention: Standardised general anaesthetic (control group)
Number of subjects: 16
Study 8188889 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Number of subjects: 60
Study 8188889 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (inactive)
Number of subjects: 60
Study 2472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg b.w.) with pentagastrin (2 micrograms/kg b.w.)
Number of subjects: 6
Study 2472262 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin infusion (control)
Number of subjects: 6
Study 29406294 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions applied during early healing stages after hemorrhoidectomy
Number of subjects: 0
Study 29406294 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions applied in postburn hypertrophic scarring with contracture
Number of subjects: 0
Study 27697876 — intervention group
Group type: EXPERIMENTAL
Intervention: ReTrain (25 sessions)
Number of subjects: 48
Study 27697876 — intervention group
Group type: COMPARATOR
Intervention: Control (exercise advice booklet)
Number of subjects: 48
Study 25683660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin D (cholecalciferol) in dosages depending upon 25(OH)‐D levels
Number of subjects: 180
Study 25683660 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 180
Study 25683660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin D (cholecalciferol)
Number of subjects: 180
Study 23442556 — intervention group
Group type: EXPERIMENTAL
Intervention: tele‐based MBCT intervention
Number of subjects: 190
Study 23442556 — intervention group
Group type: COMPARATOR
Intervention: patient education
Number of subjects: 190
Study 20184043 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasmine oil
Number of subjects: 40
Study 20184043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19767147 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 120
Study 19767147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15764759 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 26
Study 15764759 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 26
Study 12665489 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 1552
Study 12665489 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment in patients with hsCRP > or =1.11 mg/dL
Number of subjects: 1552
Study 12665489 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 1552
Study 12665489 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment in highest hsCRP quartile
Number of subjects: 1552
Study 10388979 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (2.4 pmol.kg‐1.min‐1)
Number of subjects: 6
Study 10388979 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 6
Study 8777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 8
Study 8777100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1891606 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 0
Study 1891606 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 0
Study 6646145 — intervention group
Group type: EXPERIMENTAL
Intervention: Special formula (HN 25) with low lactose content (1.8%) or virtually free of lactose (0.05%)
Number of subjects: 0
Study 6646145 — intervention group
Group type: COMPARATOR
Intervention: Partially adapted formula
Number of subjects: 0
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) visits
Number of subjects: 789
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 789
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal care (PNC)
Number of subjects: 789
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: ANC attendance associated factors
Number of subjects: 789
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth in health facilities associated factors
Number of subjects: 789
Study 31113407 — intervention group
Group type: EXPERIMENTAL
Intervention: PNC checkups
Number of subjects: 789
Study 28355594 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-technical skills seminar (NTS group, n=43)
Number of subjects: 77
Study 28355594 — intervention group
Group type: COMPARATOR
Intervention: Medical seminar (control group, n=34)
Number of subjects: 77
Study 28355594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 26846253 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch massage (TM)
Number of subjects: 50
Study 26846253 — intervention group
Group type: COMPARATOR
Intervention: Non-active transcutaneous electrical nerve stimulation (non-TENS)
Number of subjects: 50
Study 24170152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse irrigation with 2 L normal saline (<15 psi)
Number of subjects: 128
Study 24170152 — intervention group
Group type: COMPARATOR
Intervention: Standard irrigation with 2 L normal saline poured into the wound
Number of subjects: 128
Study 22451437 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY (25 g of whey protein)
Number of subjects: 24
Study 22451437 — intervention group
Group type: EXPERIMENTAL
Intervention: LEU (6.25 g whey protein with total leucine equivalent to WHEY)
Number of subjects: 24
Study 22451437 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA-LEU (6.25 g whey protein with total essential amino acids equivalent to WHEY except leucine)
Number of subjects: 24
Study 22451437 — intervention group
Group type: COMPARATOR
Intervention: Control (FAST)
Number of subjects: 24